Open AccessEffect of ClAlPcS2 photodynamic and sonodynamic therapy on hela cells
Author(s) -
Svatopluk Binder,
Barbora Hošíková,
Zuzana Malá,
Ludmila Žárská,
Hana Kolářová
Publication year - 2019
Publication title -
physiological research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.647
H-Index - 70
eISSN - 1802-9973
pISSN - 0862-8408
DOI - 10.33549/physiolres.934374
Subject(s) - photodynamic therapy , sonodynamic therapy , hela , singlet oxygen , reactive oxygen species , fragmentation (computing) , dna fragmentation , photosensitizer , programmed cell death , apoptosis , chemistry , dna damage , cytotoxic t cell , cell , viability assay , cancer research , cell damage , biophysics , oxygen , dna , photochemistry , biochemistry , in vitro , biology , ecology , organic chemistry
Photodynamic therapy (PDT) uses photosensitive substance to provoke a cytotoxic reaction causing a cell damage or cell death. The substances, photosensitizers, are usually derivates of porphyrine or phtalocyanine. Photosensitizers must be activated by light in order to produce reactive oxygen species, mainly singlet oxygen. Sonodynamic therapy (SDT) utilizes ultrasound to enhance a cytotoxic effects of compounds called sonosensitizers. In this study we investigated photodynamic and sonodynamic effect of chloraluminium phtalocyanine disulfonate (ClAlPcS(2)) on HeLa cells. DNA damage, cell viability and reactive oxygen species (ROS) production were assessed to find whether the combination of PDT and SDT inflicts HeLa cells more than PDT alone. We found that the combined therapy increases DNA fragmentation, enhances ROS production and decreases cell survival. Our results indicate that ClAlPcS(2) can act as a sonosentitiser and combined with PDT causes more irreversible changes to the cells resulting in cell death than PDT alone.